The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
A total of five observations for Goa and 17 for Monroe
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Subscribe To Our Newsletter & Stay Updated
